NIH-funded research R01 grant

Investigating how stress affects reward response and treatment with ketamine

Official title: Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine

Funded at Emory University · NIH-11003680 · Data updated 2026-11-12

This study is looking at how long-term stress can make people with major depressive disorder lose interest in things they used to enjoy, and it aims to understand how a brain chemical called glutamate is involved, especially with the hope that ketamine might help improve these feelings.

More Anhedonia research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionEmory University
NIH-funded
Lab location1 site (Atlanta, United States)
Project startMarch 1, 2022
Project endDecember 31, 2026
Funding year2025
Award (this year)$640,691
NIH project number5R01MH126083-04
Project IDNIH-11003680 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with major depressive disorder who experience symptoms of anhedonia.

Less likely to help

Patients who do not have major depressive disorder or do not experience anhedonia may not benefit from this research.

What this research studies

This research explores how prolonged exposure to stress can lead to anhedonia, a condition where individuals lose interest in activities they once enjoyed, particularly in patients with major depressive disorder (MDD). The study focuses on the role of glutamate in the brain's medial prefrontal cortex and how its response to stress differs between healthy individuals and those with MDD. By using advanced brain imaging techniques, the researchers aim to understand the biological mechanisms behind stress-induced anhedonia and how ketamine may help alleviate these symptoms. Patients may be involved in assessments that measure their brain activity and responses to stress.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments for anhedonia in patients with major depressive disorder, potentially enhancing their quality of life.

How similar studies have gone: Previous research has shown promising results in using ketamine to treat anhedonia, indicating that this approach may be effective.

Where this research is happening

  • Emory University
    Atlanta, United States
    Active

Researchers

  • Principal investigator: Treadway, Michael Tilghman — Emory University
  • Study coordinator: Treadway, Michael Tilghman

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.